Business Description
Mankind Pharma Ltd
ISIN : INE634S01028
Total Employee Number:
20,428Compare
Compare
Traded in other countries / regions
543904.India Index Membership
NIFTY 500 IPO Date
2023-05-08Description
Mankind Pharma Ltd is principally engaged in the manufacturing and trading of pharmaceuticals and health care products. The company develops, manufactures and markets pharmaceutical formulations across a wide spectrum of acute and chronic therapeutic areas, and consumer healthcare segment, which provides international quality products. It has one reportable segment Pharmaceuticals. It has presence in India, and Outside India. The company generates majority of revenue from India.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.35 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | 1.57 | |||||
Interest Coverage | 5.07 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.74 | |||||
Beneish M-Score | -1.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.5 | |||||
3-Year EBITDA Growth Rate | 22.4 | |||||
3-Year EPS without NRI Growth Rate | 14 | |||||
3-Year FCF Growth Rate | 33 | |||||
3-Year Book Growth Rate | 28.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.81 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.82 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.47 | |||||
9-Day RSI | 52.01 | |||||
14-Day RSI | 48.6 | |||||
3-1 Month Momentum % | 3.96 | |||||
6-1 Month Momentum % | 9.88 | |||||
12-1 Month Momentum % | -0.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.07 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.34 | |||||
Days Inventory | 184.42 | |||||
Days Sales Outstanding | 42.67 | |||||
Days Payable | 112.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.04 | |||||
Dividend Payout Ratio | 0.02 | |||||
5-Year Yield-on-Cost % | 0.04 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -2.84 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.2 | |||||
Operating Margin % | 19.91 | |||||
Net Margin % | 13.86 | |||||
EBITDA Margin % | 27.37 | |||||
FCF Margin % | 16.18 | |||||
OCF Margin % | 21.18 | |||||
ROE % | 13.35 | |||||
ROA % | 7.24 | |||||
ROIC % | 9.23 | |||||
3-Year ROIIC % | 5.73 | |||||
ROC (Joel Greenblatt) % | 61.14 | |||||
ROCE % | 14.41 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 48.31 | |||||
Forward PE Ratio | 41.26 | |||||
PE Ratio without NRI | 45.92 | |||||
PEG Ratio | 2.8 | |||||
PS Ratio | 6.7 | |||||
PB Ratio | 6.05 | |||||
Price-to-Tangible-Book | 600.3 | |||||
Price-to-Free-Cash-Flow | 41.39 | |||||
Price-to-Operating-Cash-Flow | 31.61 | |||||
EV-to-EBIT | 32.94 | |||||
EV-to-Forward-EBIT | 27.78 | |||||
EV-to-EBITDA | 25.65 | |||||
EV-to-Forward-EBITDA | 24.05 | |||||
EV-to-Revenue | 7.02 | |||||
EV-to-Forward-Revenue | 6.31 | |||||
EV-to-FCF | 43.19 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.17 | |||||
Price-to-Graham-Number | 36.39 | |||||
Earnings Yield (Greenblatt) % | 3.04 | |||||
FCF Yield % | 2.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mankind Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 147,378.8 | ||
| EPS (TTM) (₹) | 49.42 | ||
| Beta | 0.4705 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 22.27 | ||
| 14-Day RSI | 48.6 | ||
| 14-Day ATR (₹) | 52.150474 | ||
| 20-Day SMA (₹) | 2407.615 | ||
| 12-1 Month Momentum % | -0.07 | ||
| 52-Week Range (₹) | 1909.7 - 2674 | ||
| Shares Outstanding (Mil) | 413 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mankind Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mankind Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 1.000000 Cash Dividend | 2025-08-08 | 2,537.80 (-0.72%) |
Show
Entries
Mankind Pharma Ltd Frequently Asked Questions
What is Mankind Pharma Ltd(NSE:MANKIND)'s stock price today?
The current price of NSE:MANKIND is ₹2419.20. The 52 week high of NSE:MANKIND is ₹2674.00 and 52 week low is ₹1909.70.
When is next earnings date of Mankind Pharma Ltd(NSE:MANKIND)?
The next earnings date of Mankind Pharma Ltd(NSE:MANKIND) is .
Does Mankind Pharma Ltd(NSE:MANKIND) pay dividends? If so, how much?
The Dividend Yield %  of Mankind Pharma Ltd(NSE:MANKIND) is 0.04% (As of Today), Highest Dividend Payout Ratio of Mankind Pharma Ltd(NSE:MANKIND) was 0.02. The lowest was 0.02. And the median was 0.02. The  Forward Dividend Yield % of Mankind Pharma Ltd(NSE:MANKIND) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Mankind Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers